The 12-month price targets, analyzed by analysts, offer insights with an average target of $23.58, a high estimate of $25.00, ...

Kenvue (KVUE), the company behind Tylenol and Neutrogena, announced that Thibaut Mongon had left the company, naming Kirk ...

Kenvue (NYSE:KVUE) recently experienced a 2% price increase over the past week, a move that coincides with notable executive changes. The replacement of the CEO with Kirk L. Perry as interim CEO, ...

Kenvue has five brands that generate over $1 billion in sales—Johnson’s, Neutrogena, Listerine, Tylenol, and Aveeno—as well as a number of brands that generate over $400 million in sales: Nicorette, ...

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

So far this year, the favorite demand for activist investors has been a call for board changes, appearing in 43% of campaigns ...

We believe Perrigo is in fine financial health. At the end of 2024, the company had roughly $560 million in cash and equivalents with about $3.3 billion in long-term debt. Its balance sheet was in a ...

After years of post-COVID-19 normalization and the impact of its Kenvue spinoff, Johnson & Johnson’s (NYSE: JNJ) stock price ...

Late June, 2025, 25 of the 55 Dividend Kings were tagged "safer" for dividends as they showed positive one-year returns and free-cash-flow-yields greater-than dividend-yields. Furthermore, YCharts 7/1 ...

Asian shares are trading mostly lower as worries about President Donald Trump’s latest updates to his tariffs weighed on ...

In a testament to its enduring strength and adaptive strategy, Johnson & Johnson (NYSE: JNJ) today announced a strong ...

“The Board’s strategic review is underway, and we are considering a broad range of potential alternatives, including ways to ...